Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A. Philip, Pascal Hammel, Edward Kim et al.|The Lancet. Gastroenterology & hepatology|2020Cited by 249
Phase II LAPACT trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).Pascal Hammel, Philip Agop Philip, Jill Lacy et al.|Journal of Clinical Oncology|2018Cited by 32
nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT TrialP. A. Philip, Pascal Hammel, Jill Lacy et al.|Annals of Oncology|2017Cited by 3